By Chelsea Naso ( March 24, 2015, 5:26 PM EDT) -- Cellectis SA boosted the target for its U.S. initial public offering to nearly $200 million Tuesday, increasing the number of American depositary shares it plans to sell as the France-listed company's common stock climbs on the Paris Euronext and U.S.-listed cancer immunotherapy treatment developers' shares rally....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.